
Is disclosure non-compliance harming drug development?
Ali Pashazadeh, Founder and CEO of Treehill Partners, explores how clinical trial disclosure non-compliance is placing major pressures on clinical development, biopharma investment, and patient access to life saving therapies. Clinical trial disclosure non-compliance is rarely discussed and often ignored as a problem in the drug development sector. It is,… Read More














